Bob Soh
Senior Investment Manager @ Brandon Capital
Melbourne, Australia
Bob Soh is a Series A investor at Brandon Capital in Melbourne focused on Medical and Biopharma. Bob joined Brandon Capital in 2016. Before joining Brandon Capital, Bob worked at Nucleus Network, Australia’s largest clinical trials unit. He was an investigator in over 100 early-phase clinical trials, including as PI. He was heavily involved in various aspects of the business, including overseeing its clinical operations, business development,and expanding Nucleus Network’s trial capabilities.During his time at Nucleus Network, he was concurrently appointed as the acting CEO for Cardiora, a Brandon Capital investee company developing therapies for heart failure. He successfully led Cardiora through phase 2 clinical trials and successfully led the Company’s FDA regulatory and IP strategy. The program was subsequently licensed to a specialty pharmaceutical company.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Bob Soh invests in
Stages Bob Soh invests in
Countries Bob Soh invests in
Investment Focus
Industry
- Medical 1 (50%)
- Biopharma 1 (50%)
- Landscaping 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Glyscend Therapeutics
|
Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel. | $19.8M / Series A / Jun 11, 2020 | |
|
Glyscend Therapeutics
|
Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel. | $19.8M / Series A / Jun 11, 2020 |
Co-Investors
About Brandon Capital
Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.
Brandon Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chris Nave
Partner, Managing Director & Co-Founder
|
|||
Robert Daniels
Venture Partner
|
|||
Stephen Thompson
Partner
|
|||
|
Bob Soh
Senior Investment Manager
|
|||
Darren Kelly
Entrepreneur in Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bob Soh invest in?
Bob Soh invests primarily in Medical, Biopharma and Landscaping startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Bob Soh last invest?
The most recent investment recorded for Bob Soh closed in Jun 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
